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Background
There is a permanent need for improvement in effective
pain management that calls for implication of recent
advances in the understanding of endogenous morphine-
like substances. Using the technique of ''reverse physiol-
ogy'' identification of an orphan, opioid-receptor-like 1
receptor (ORL1, recently named as OP4/NOP), and isola-
tion of its endogenous agonist orphanin FQ/nociceptin
(NC) opened a new era in opioid pharmacology. In recog-
nition of the involvement of NOP-NC system in a wide
range of physiological, and pathophysiological processes,
the nociceptinergic system is considered an important
new target for drug development in pain control, mor-
phine-withdrawal, anxiety, depression, cognitive impair-
ment, body mass control, cough suppression,
hypertension, heart failure and ischemic brain injury.
Methods
We conceptionalized that elucidation of (patho)physio-
logical conditions/human disorders with changes in
endogenous levels of NC can give significant contribution
to drug targeting. [125I]NC-RIA and HPLC methods were
used for measurements.
Results
In Wistar rats both in the central nervous system (CSF)
and the periphery (blood plasma) NC levels reached the
adult level by the age of 12 weeks. Plasticity of unmatured
NOP receptors was evidenced in neonatal hormonal
imprinting studies with NC. In patients with chronic liver
disorders of different etiology (Wilson's disease, primary
biliary cirrhosis) plasma NC was found to be elevated,
and extremely high levels were observed in hepatocellular
carcinoma patients compared to age-matched healthy
controls. The functional role of circulating NC in primary
neurovascular headaches (migraine and cluster headache
patients) was also evidenced. Plasma NC levels in acute
stroke and transient ischemic attack patients were found
to be elevated compared to healthy controls; however, sig-
nificantly lower NC levels were observed in atheroscle-
rotic patients with chronic limb ischemia in both the
plasma and blood vessels.
Conclusion
The observed changes in endogenous NC levels designate
the NOP-NC system as a potential new target in therapy.
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